Investigation of Serum NO, ADMA and Apelin Levels in Thyroid Dysfunction

Arzu Şahin, Mustafa Gül, Ömer Akyol, Elif Şimsek, Fikret Çelebi, Akar Karakoç


Thyroid gland diseases are among the most common endocrine diseases and still continue to be an important health problem especially in developing countries. It was aimed to investigate serum NO, ADMA and Apelin levels in patients with thyroid dysfunction. This study was conducted with 150 thyroid patients and 50 healthy subjects. Study subjects were divided into three groups; control (n=50), hyperthyroid ( n=75) and hypothyroid (n=75). Serum TSH, FT3, FT4   levels  were  measured  by  chemiluminescence  method  NO  level  were  measured  by spectrophotometric method, ADMA and apelin levels were measured by ELISA. Serum NO levels were higher in hypothyroid group than in hyperthyroid group, and the difference was statistically significant. Serum ADMA levels of the hyperthyroid group were significantly higher than the other two groups and the difference was statistically significant. The levels  of  serum  apelin  were  statistically significantly higher in the hyperthyroid group than the other two groups. In patients with hyperthyroidism, ADMA and Apelin levels were higher, while NO level was lower. However, NO level was higher in patients with hypothyroidims than the other two groups. Apelin, which has been emphasized  as  a  preventive  and  therapeutic  agent  particularly  for  the cardiovascular system, might have increased in hyperthyroid patients, regardless of NO, to protect cardiovascular system from possible adverse effects of ADMA.

Keywords: Asymmetric dimethylarginine, apelin, nitric oxide, thyroid dysfunction

DOI: 10.7176/JMPB/67-03

Publication date:August 31st 2020

Full Text: PDF
Download the IISTE publication guideline!

To list your conference here. Please contact the administrator of this platform.

Paper submission email:

ISSN 2422-8427

Please add our address "" into your email contact list.

This journal follows ISO 9001 management standard and licensed under a Creative Commons Attribution 3.0 License.

Copyright ©